The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://journals.asm.org/doi/10.1128/jcm.02479-21
Here is a list of approved FDA LFTs , note their ability to detect the super spreaders against what is considered people with a high viral load. Now if anyone can produce a test capable of identifying the super spreaders who spout a lower viral load, would this be classed as a winner ?
Dvrg also have a MoU with Abingdon Health for lateral flow tests. All just a side show now, but who knows.
"I’m pretty sure they’ve decided not to tell the market about anything in the diagnostics pipeline ..." I can picture AS standing there arms crossed saying "you can sod off, I'm not saying a bloody word about diagnostics until the deals have been inked"
From March 2022.
Just to clarify, i emailed this question to DVRG and was told by GB they are working with both companies. They can be used as binding agents on the MicrotoxPD chips that capture the dangerous pathogens, such as SARS-CoV-2 and many other biomarkers.
We work with both companies.
Not polio then? Thought DVGE might have been behind the latest push for more vaccination.
don't know if still valid but :
The optofluidic chips at the heart of the system are covered in a protein – Aptamer, Affirmer – that is specifically developed to bind the Spike Protein of SARS CV 2 with 100% specificity. Aptamers and Affirmers are already being developed for E. coli, Legionella, Cryptosporidium, Norovirus and PMMoV.
The Microtox PD range also effectively detects chemicals and other substances at lower molecule levels. With 100% specificity, it can zero in on substances that were not measurable or may be newly introduced. Medicines, pesticides, personal care, hormones, plasticizers, detergents, food additives, surfactant product compounds end up in wastewater systems, potentially making their way into water sources.
https://www.modernwater.com/2021/10/06/monitoring-wastewater-to-provide-faster-real-time-detection-of-covid-19-and-other-pathogens/
Weird. I thought I’d woken up and maybe 12 months of posts had been deleted, leaving this up top!
AS has said finding reagents is quick and easy. It’s sorting out the final test design and getting regulatory approvals that takes a long time.
I’m pretty sure they’ve decided not to tell the market about anything in the diagnostics pipeline until it launches, at this stage. Don’t want to remind people of the LFT disappointment, or distract them from the real value driver which is the ongoing trial.
Show - yes. They’re using aptamers.
We moved on from this link months ago.
That is also my recollection.
Some time ago Deep Water (previously Integumen), was working with both Aptamer Group and Avacta (Affimers), but I seem to remember that they proceeded just with Aptamer Group.
They issued an RNS but can’t locate it.
Found this quickly:
https://www.proactiveinvestors.co.uk/companies/news/922426/integumen-signs-material-transfer-agreement-with-aptamer-group-for-new-coronavirus-kit-922426.html
Where is it confirmed that we are not working with Deepverge ?
From Deepverge BB...comment made by their CEO.
'Wich includes both the PD for water contamination and BT for the multiplex biomarker detection, of which SARS-CoV-2 is but one target pathogen. This is a digital health medical device and rolling it out for a single biomarker is not viable when it is to be used in a clinical diagnostic laboratory or eventually small enough to be used in an GP office.
That is nearly 10 times what was spent in R&D in 2020 Some of that is on BT. Progress is being made and while it may not be detecting COVID in test centers we are falling behind on delivery taking into account the time it takes to bring a medical device to market.'
Avacta and Deepverge still working together. Interesting statement made by Deepverge may be a bit of a clue as to what Avacta might be looking at too.
Pig spit ..
It would be excellent to see Av testing’ in train’ again, but fear John Bell / Porton Down mess up has put the kaibosh on options gf.
GLA
Remember that boat as it vanished over the horizon taking with it the expectations of massive sales in LFTs, well the Yanks have boarded it.
https://www.nbcnews.com/health/health-news/fda-says-three-negative-rapid-tests-needed-asymptomatic-covid-rcna42734
According to the recommendation made by the FDA they will need another two boats to sail in. Interesting how the statement made by AS suggesting testing will be around for years to come appears to be coming true.
He also said re-developing the test to restore that performance and in doing it in a manner as robust as it can be too future variants.
Why did he make this claim, could it be because Avct know a lot more about the virus. The antigens of interest and because the Affimer in the test is un-effected this has taught them quite a lot. Which epitope, which part of the antigen is least vulnerable to mutation so we can apply some thought to generate a second agent. One that gives us more future proving going forward. Full steam ahead.